I-Mab Announces New Auditor for Strategic Growth
Company Announcements

I-Mab Announces New Auditor for Strategic Growth

I-MAB (IMAB) has released an update.

I-Mab, a U.S.-based global biotech firm focusing on cancer immunotherapies, has appointed PricewaterhouseCoopers LLP as its independent auditor for fiscal year 2024. This move is part of I-Mab’s strategic shift to reinforce its presence as a U.S. biotech entity, with no reported issues from the previous auditor. The company leaders express confidence in PwC’s alignment with shareholder interests and the firm’s capabilities to support I-Mab’s long-term growth objectives.

For further insights into IMAB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskI-Mab Appoints New CEO to Drive Cancer Therapy Goals
TheFlyI-Mab names Sean Fu as permanent CEO
TheFlyInhibrx prevails in trade secret case with I-Mab
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App